Work

Pos1147 Efficacy of Cenerimod in Patients With High Ifn-1 Gene Expression Signature and High Anti-dsdna Antibody Levels: Post-hoc Analysis From a Phase 2 Study

Year: 2023

Type: conference-abstract

Source: Annals of the Rheumatic Diseases

DOI: 10.1136/annrheumdis-2023-eular.3823

Authors: A. Askanase, D. D'cruz, K. Kalunian, J. Merrill, S. Navarra, C. Cahuzac, P. Cornelisse, D. Strasser, L. Trokan, O. Berkani

Institutions: Columbia University Irving Medical Center, Columbia University, Guy's Hospital, St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust, University of California San Diego, Oklahoma Medical Research Foundation, University of Santo Tomas, Idorsia Pharmaceuticals Ltd (Switzerland)

Language: English

Topic: Systemic Lupus Erythematosus Research

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Celgene, Idorsia Pharmaceuticals, Genentech

OpenAlex ID: W4379793413

Cites:

Cited by: 2

Related to: 10